Advertisement

Journal of Clinical Immunology

, Volume 38, Issue 8, pp 854–863 | Cite as

Report of a Chinese Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome

  • Ying Wang
  • Wenjie Wang
  • Luyao Liu
  • Jia Hou
  • Wenjing Ying
  • Xiaoying Hui
  • Qinhua Zhou
  • Danru Liu
  • Haili Yao
  • Jinqiao Sun
  • Xiaochuan Wang
Original Article
  • 66 Downloads

Abstract

Purpose

We aimed to report the clinical manifestations and immunological features of activated phosphatidylinositol 3-kinase δ syndrome 1 (APDS1) in a Chinese cohort. Moreover, we investigated the efficacy and safety of rapamycin therapy for Chinese patients with APDS1.

Methods

Fifteen Chinese patients with APDS1 from 14 unrelated families were enrolled in this study. These patients were diagnosed based on clinical features, immunological phenotype, and whole-exome sequencing. Four patients were treated with rapamycin, and the clinical efficacy and safety of rapamycin were observed. The changes of phosphorylation of Akt and mammalian target of rapamycin (mTOR) signaling pathway after rapamycin treatment were detected by flow cytometry and real-time PCR.

Results

The common clinical manifestations of the patients included lymphadenopathy (93%), recurrent sinopulmonary infections (93%), hepatosplenomegaly (93%), and diarrhea (78%). Epstein-Barr virus (EBV) (80%) and fungus (Aspergillus) (47%) were the most common pathogens. Immunological phenotype included elevated Immunoglobulin (Ig) M levels (100%), decreased naive T cells, increased senescent T cells, and expanded transitional B cells. Whole-exome sequencing indicated that 13 patients had heterogeneous PIK3CD E1021K mutations, 1 patient had heterogeneous E1025G mutation and 1 patient had heterogeneous Y524N mutation. Gain-of-function (GOF) PIK3CD mutations increased the phosphorylation of the Akt-mTOR signaling pathway. Four patients underwent rapamycin therapy, experiencing substantial improvement in clinical symptoms and immunological phenotype. Rapamycin inhibited the activated Akt-mTOR signaling pathway.

Conclusions

We described 15 Chinese patients with APDS1. Treatment with the mTOR inhibitor rapamycin improved patient outcomes.

Keywords

Activated phosphoinositide 3-kinase δ syndrome primary immunodeficiency PIK3CD gene rapamycin 

Notes

Acknowledgments

Many thanks to the patients and their parents.

Funding Information

This study was supported by the National Natural Science Foundation of China (81471482), Science and Technology Commission of Shanghai Municipality (14411965400), and Shanghai Hospital Development Center (SHDC12016228).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Supplementary material

10875_2018_568_Fig7_ESM.png (228 kb)
Supplemental Fig. 1

Changes of the expression of CD57 on T cells. a and b: The expression of CD57 on the CD4+ T cells/CD8+ T cells in four patients with rapamycin treatment at 0 month, 3 months, 6 months and 12 months. P2 stopped rapamycin therapy after 6 months, and p10 received rapamycin therapy for only 3 months. (PNG 227 kb)

10875_2018_568_MOESM1_ESM.tif (3.8 mb)
High resolution image (TIF 3867 kb)
10875_2018_568_Fig8_ESM.png (295 kb)
Supplemental Fig. 2

CD57 expression on T cells in APDS1 patients. a and b: CD57 expression on CD4+ T cells/CD8+ T cells in a healthy control and patient 5. Proportion of CD57 + CD4+ T cells/CD57 + CD8+ T cells was compared at 3 months, 6 months and 12 months of rapamycin treatment. (PNG 295 kb)

10875_2018_568_MOESM2_ESM.tif (327 kb)
High resolution image (TIF 326 kb)
10875_2018_568_Fig9_ESM.png (412 kb)
Supplemental Fig. 3

Flow cytometry analysis showing levels of phospho-AKT (pAKT) protein (Ser473 and Thr308) and pS6 (Ser235/236 and Ser240/244) in CD3+ T cells in patient 10 and a healthy control. Levels of pAKT and pS6 were analyzed without and with rapamycin at 3 months. (PNG 412 kb)

10875_2018_568_MOESM3_ESM.tif (2.1 mb)
High resolution image (TIF 2157 kb)
10875_2018_568_MOESM4_ESM.xlsx (10 kb)
Supplementary Table 1 (XLSX 9 kb)
10875_2018_568_MOESM5_ESM.xlsx (10 kb)
Supplementary Table 2 (XLSX 9 kb)
10875_2018_568_MOESM6_ESM.xlsx (10 kb)
Supplementary Table 3 (XLSX 10 kb)
10875_2018_568_MOESM7_ESM.xlsx (12 kb)
Supplementary Table 4 (XLSX 12 kb)
10875_2018_568_MOESM8_ESM.xlsx (11 kb)
Supplementary Table 5 (XLSX 10 kb)

References

  1. 1.
    Angulo I, Vadas O, Garçon F, Banham-Hall E, Plagnol V, Leahy TR, et al. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science. 2013;342(6160):866–71.CrossRefGoogle Scholar
  2. 2.
    Lucas CL, Chandra A, Nejentsev S, Condliffe AM, Okkenhaug K. PI3Kδ and primary immunodeficiencies. Nat Rev Immunol. 2016;16(11):702–14.CrossRefGoogle Scholar
  3. 3.
    Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: a large patient cohort study. J Allergy Clin Immunol. 2017;139(2):597–606.CrossRefGoogle Scholar
  4. 4.
    Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol. 2014;15(1):88–97.CrossRefGoogle Scholar
  5. 5.
    Takeda AJ, Zhang Y, Dornan GL, Siempelkamp BD, Jenkins ML, Matthews HF, et al. Novel PIK3CD mutations affecting N-terminal residues of p110δ cause activated PI3Kδ syndrome (APDS) in humans. J Allergy Clin Immunol. 2017;140(4):1152–6.CrossRefGoogle Scholar
  6. 6.
    Hartman HN, Niemela J, Hintermeyer MK, Garofalo M, Stoddard J, Verbsky JW, et al. Gain of function mutations of PIK3CD as a cause of primary sclerosing cholangitis. J Clin Immunol. 2015;35(1):11–4.CrossRefGoogle Scholar
  7. 7.
    Maccari ME, Abolhassani H, Aghamohammadi A, Aiuti A, Aleinikova O, Bangs C, et al. Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase δ syndrome: the European Society for Immunodeficiencies-Activated Phosphoinositide 3-kinase δ syndrome registry. Front Immunol. 2018;9:543.CrossRefGoogle Scholar
  8. 8.
    Sun J, Ying W, Liu D, Hui X, Yu Y, Wang J, et al. Clinical and genetic features of 5 Chinese patients with X-linked lymphoproliferative syndrome. Scand J Immunol. 2013;78(5):463–7.CrossRefGoogle Scholar
  9. 9.
    Sun J, Wang Y, Liu D, Yu Y, Wang J, Ying W, et al. Prenatal diagnosis of X-linked chronic granulomatous disease by percutaneous umbilical blood sampling. Scand J Immunol. 2012;76(5):512–8.CrossRefGoogle Scholar
  10. 10.
    Dulau Florea AE, Braylan RC, Schafernak KT, Williams KW, Daub J, Goyal RK, et al. Abnormal B-cell maturation in the bone marrow of patients with germline mutations in PIK3CD. J Allergy Clin Immunol. 2017;139(3):1032–5.CrossRefGoogle Scholar
  11. 11.
    Luo Y, Xia Y, Wang W, Li Z, Jin Y, Gong Y, et al. Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase δ syndrome. Clin Immunol. 2018;197:60–7.CrossRefGoogle Scholar
  12. 12.
    Finlay DK, Rosenzweig E, Sinclair LV, Feijoo-Carnero C, Hukelmann JL, Rolf J, et al. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J Exp Med. 2012;209(13):2441–53.CrossRefGoogle Scholar
  13. 13.
    Kang S, Denley A, Vanhaesebroeck B, Vogt PK. Oncogenic transformation induced by the p110beta, −gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A. 2006;103(5):1289–94.CrossRefGoogle Scholar
  14. 14.
    Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117(2):591–4.CrossRefGoogle Scholar
  15. 15.
    Astle MV, Hannan KM, Ng PY, Lee RS, George AJ, Hsu AK, et al. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene. 2012;31(15):1949–62.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Clinical ImmunologyChildren’s Hospital of Fudan UniversityShanghaiChina

Personalised recommendations